UPDATE: Wal-Mart, Best Buy gain on Black Friday
Vertex Sells INCIVO ® Product Royalty Rights for $152 Million
Good day, ladies and gentlemen. Welcome to the Vertex Pharmaceuticals Incorporated Third Quarter 2013 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a ...
StockInvestor editor Matt Coffina and senior biotech analyst Karen Andersen discuss Gilead's growing competitive advantages.
This screen finds companies ready to take advantage when major provisions of law take effect in 2014.
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Week ending Oct. 27: Stocks held in check by jump oil prices, weak housing market.
Increased investor inflows and portfolio reshuffling (driven in part by a fairly valued market), has added breadth to the high-conviction and new-money purchases we've seen so far from our top managers.